Search Results for 'Discontinuation-Ticagrelor'

Discontinuation-Ticagrelor published presentations and documents on DocSlides.

Long-Term Tolerability of

Long-Term Tolerability of

by briana-ranney

Ticagrelor. for Secondary Prevention: . Insights...

One-month Ticagrelor Monotherapy After PCI in Acute Coronary Syndromes:

One-month Ticagrelor Monotherapy After PCI in Acute Coronary Syndromes:

by yvonne

Principal Results From the Double-blind, Placebo-c...

Cangrelor in Patients with Coronary Artery Disease Pre-treated with Ticagrelor: The Switching Antip

Cangrelor in Patients with Coronary Artery Disease Pre-treated with Ticagrelor: The Switching Antip

by beatrice

Luis Ortega-Paz, MD, PhD. 1. ; Francesco Franchi, ...

Prasugrel vs ticagrelor in acute coronary syndromes

Prasugrel vs ticagrelor in acute coronary syndromes

by tawny-fly

Giuseppe . Biondi-Zoccai. , MD. Sapienza Universi...

Ticagrelor compared with clopidogrel in patients with acute

Ticagrelor compared with clopidogrel in patients with acute

by tatyana-admore

PLAT. elet Inhibition and patient . O. utcomes tr...

ACCP Cardiology PRN Journal Club

ACCP Cardiology PRN Journal Club

by marina-yarberry

ACCP Cardiology PRN Journal Club 27 September 20...

Adverse drug reactions and discontinuation of Implanon NXT

Adverse drug reactions and discontinuation of Implanon NXT

by rowen

®. among users in Gauteng and. KwaZulu-Natal Pro...

Francesco Franchi, MD, Fabiana Rollini, MD, Jose Rivas Rios, MD, Andrea Rivas, MD,

Francesco Franchi, MD, Fabiana Rollini, MD, Jose Rivas Rios, MD, Andrea Rivas, MD,

by shiloh201

Malhar Agarwal, MD, Megha Kureti, MD, Deepa Nagara...

Aspirin (n = 6,610) Ticagrelor

Aspirin (n = 6,610) Ticagrelor

by danya

(n . = 6,589). SOCRATES. Primary outcome, death, M...

Ticagrelor ADDED to aspirin in Acute NON-SEVERE ISCHEMIC Stroke OR TIA OF ATHEROSCLEROTIC

Ticagrelor ADDED to aspirin in Acute NON-SEVERE ISCHEMIC Stroke OR TIA OF ATHEROSCLEROTIC

by eloise

ORIGIN. Pierre . Amarenco. , Hans . Denison. , . S...

by eddey

coronary intervention PCI1920 As new antithromboti...

T icagrelor W ith Asp I

T icagrelor W ith Asp I

by terrificycre

rin or A. L. one . I. n Hi. GH. -Risk Patients Aft...

Antiplatelet Agents Mohammad Sistanizad

Antiplatelet Agents Mohammad Sistanizad

by blindnessinfluenced

Associate Professor of Clinical Pharmacy,. SBMU. C...

Reduction in Ischemic Events with

Reduction in Ischemic Events with

by natalia-silvester

Ticagrelor. in Diabetic Patients from the PEGASU...

by lindy-dunigan

safety study . of . ticagrelor's. degradation co...

by kittie-lecroy

safety study . of . ticagrelor's. degradation co...

Quality Improvement and Practice-Based Research in Neurology Using the EMR

Quality Improvement and Practice-Based Research in Neurology Using the EMR

by ariel

Demetrius (“Jim”) M. Maraganore, MD. Ruth Cain...

by elise

44444444444444444444FeverCoughShortness of BreathO...

Discontinuation of CRRT and/or Transition to Other Dialytic

Discontinuation of CRRT and/or Transition to Other Dialytic

by giovanna-bartolotta

Patrick D Brophy, MD, MHCDS. Director Pediatric N...

Progress and future agenda

Progress and future agenda

by faustina-dinatale

Medicines shortages in manufacturing. "global sto...

Application for course discontinuation

Application for course discontinuation

by marina-yarberry

ADM 22 - V 0 4 / 12 Course Discontinuation Form v ...

Abbreviations: AF: atrial fibrillation, ACS: acute coronary syndrome, BD: twice daily, CAD: corona

Abbreviations: AF: atrial fibrillation, ACS: acute coronary syndrome, BD: twice daily, CAD: corona

by holly

CrCl. : creatinine clearance, CTO: chronic total o...

Practice Plus Webinar June 23

Practice Plus Webinar June 23

by bitsy

rd. . 2021 . Steve Williams. Lead Clinical Pharma...

Cangrelor : Friend or Foe? -

Cangrelor : Friend or Foe? -

by ariel

Cangrelor. : Not the CHAMPION We Hoped For. James ...

Expert Discussion on Antiplatelet for ACS Patients: Controversies for Asian Patients

Expert Discussion on Antiplatelet for ACS Patients: Controversies for Asian Patients

by GratefulHeart

Akhtar . Fajar. . Muzakkir. New ESC NSTEMI Guidel...

Antiplatelet Therapy for Secondary Prevention in the First Year Following

Antiplatelet Therapy for Secondary Prevention in the First Year Following

by calandra-battersby

Antiplatelet Therapy for Secondary Prevention in...

Bonferroni: Friend or Foe?

Bonferroni: Friend or Foe?

by alexa-scheidler

Multiple Testing in Cardiovascular Medicine. Dhru...

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban

by celsa-spraggs

Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...

STEMI Update 2017 Cardiology Today

STEMI Update 2017 Cardiology Today

by alida-meadow

Michael C Fraizer, MD. Iowa Heart Center. Feb 4, ...

ACCP Cardiology PRN Journal Club

ACCP Cardiology PRN Journal Club

by tatiana-dople

Announcements . Thank you attending the ACCP Card...

Canadian Diabetes Association Clinical Practice Guidelines

Canadian Diabetes Association Clinical Practice Guidelines

by test

Acute Coronary Syndromes and Diabetes. Chapter 26...

Comments on Methodological Challenges in Clinical Trials for CIPN

Comments on Methodological Challenges in Clinical Trials for CIPN

by paul654

n. ges in Clinical . T. rials for CIPN. Michael P....

Charlotte Verroken Department

Charlotte Verroken Department

by violet

of . Endocrinology. UZ Gent. Bisphosphonates vs. ....

Herstel van psychose z onder/ met zo min mogelijk

Herstel van psychose z onder/ met zo min mogelijk

by brooke

antipsychotica. Disclosure. I . prescribe. . anti...

Stopping over medication of people with learning disabilities and autism

Stopping over medication of people with learning disabilities and autism

by roy

Core Messages. June 16. The Goal of the . STOMPLD ...

Christophe Hézode Hôpital Henri Mondor,

Christophe Hézode Hôpital Henri Mondor,

by isabella

Créteil, France. Paris, 30 January 2012. Triple t...

Guidance on Research FollowUp

Guidance on Research FollowUp

by fiona

Defining a follow-up period is important to the re...

COSTEFFECTIVENESS MODEL COMPARING SUBAITRACONAZOLE SUBAITRA VERSU

COSTEFFECTIVENESS MODEL COMPARING SUBAITRACONAZOLE SUBAITRA VERSU

by jasmine

CONCLUSIONSSUBA-ITRAestimateswereassociatedwithsma...

Protocol Requirements for Product Holds/Discontinuations

Protocol Requirements for Product Holds/Discontinuations

by yoshiko-marsland

MTN-025. Objectives. Identify the conditions that...

Efficacy and safety of switching from boosted-protease inhibitors plus

Efficacy and safety of switching from boosted-protease inhibitors plus

by calandra-battersby

emtricitabine. /tenofovir . disoproxil. fumarate...